Article · 2012
Editor
Haval Shirwan
Professor, Department of Microbiology and Immunology, University of Louisville, USA
About
As published by the journal they serve.
Dr Shirwan is Dr Michael and Joan Hamilton Endowed Chair in Autoimmune Disease Professor of Microbiology and Immunology and the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his graduate studies at the University of California in Santa Barbara CA and postdoctoral studies at California Institute of Technology in Pasadena CA. He joined the University of Louisville in 1998 after holding academic appointments at various institutions in the United States. Dr Shirwans research focuses on the modulation of immune system for the treatment of immunebased diseases with particular focus on type 1 diabetes transplantation and development of vaccines against infections and cancer. Dr Shirwan is widely published lectured at various national/international conferences served on various federal and nonprofit funding agencies and is on the Editorial Board of nine scientific journals He is a member of several national and international societies and recipient of various awards.
Research interests
Journals they serve
The seats these journals name them in.
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article · 2019
PLG scaffolds engineered with an immunomodulatory molecule as an effective means of establishing localized tolerance to pancreatic islet grafts
Article · 2018
Pancreatic islets engineered with a chimeric PD-L1 protein overcome rejection in allogeneic recipients
Article · 2018
Induction of tolerance to allogeneic islet grafts using an immunomodulatory biomaterial
Article · 2017
Targeted deletion of pathogenic T effector cells as a robust means of allograft tolerance
Article · 2017
SA-4-1BBL as an adjuvant platform for the development of vaccines
Article · 2016
Mechanistic basis of allotolerance induced by SA-FasL-engineered pancreatic islets
Article · 2016
Specific targeting of pathogenic T-cells for the induction of tolerance to pancreatic islet grafts for the treatment of type-1 diabetes
Article · 2013
Systemic immunomodulation with SA-FasL-engineered donor splenocytes as an effective means of inducing tolerance to cardiac allografts
Article · 2013
Engineering cells and tissues with exogenous immunomodulatory proteins for the induction of tolerance to auto and alloantigens
Article · 2015
ProtEx™ technology as an effective means of engineering bone marrow cells with immunoregulatory molecules for the establishment of mixed hematopoietic chimerism
Article · 2015
Apoptosis as an effective means of inducing tolerance to pancreatic islets for the treatment of type 1 diabetes
Article · 2012
The direct display of immunological ligands on allogeneic hematopoietic stem cells and tissues as an effective means of inducing tolerance
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.